Written and maintained by CASRAI Editorial Board
Last updated
This page describes clinical standards, diagnostic criteria, and respiratory research protocols; it is not individual medical advice.
Short answer
The Global Initiative for Asthma (GINA) is an international medical collaborative launched in 1993 by the World Health Organization (WHO) and the National Heart, Lung, and Blood Institute (NHLBI). GINA issues annually updated evidence-based strategies establishing objective diagnostic criteria, the continuous Assess-Adjust-Review management loop, and anti-inflammatory reliever (AIR) pathways while advising against short-acting beta2-agonist monotherapy.
Definition and scope
The Global Initiative for Asthma (GINA) is an independent organization whose Science Committee conducts ongoing systematic literature reviews to publish annual global strategies for asthma management and prevention. Asthma is a heterogeneous chronic inflammatory disease defined by variable respiratory symptoms (wheeze, shortness of breath, cough) paired with variable expiratory airflow limitation.
GINA’s scope spans pediatric, adolescent, and adult care across clinical practice and clinical trial design. Rather than issuing static regional guidelines, GINA provides an annual international benchmark that standardizes symptom control metrics, exacerbation risk reduction, and severe asthma phenotyping. Key trial methodologies used in respiratory studies are covered in our guide to pragmatic trials.
How it works or how it is used in practice
GINA translates clinical trial and immunological evidence into practice through three operational pillars:
1. Objective Diagnostic Verification
GINA requires objective proof of variable expiratory airflow limitation before starting controller therapy:
- Spirometry: Documented airflow limitation via reduced FEV1/FVC (<0.75–0.80 in adults).
- Bronchodilator Reversibility (BDR): Documented FEV1 increase >12% and >200 mL after inhaling 200–400 mcg albuterol/salbutamol. For pulmonary volumes complementing spirometry, consult our guide on the body plethysmograph.
- Peak Flow Variability: Average daily diurnal peak expiratory flow (PEF) variability >10% over 1 to 2 weeks.
- Bronchial Provocation: Positive challenge testing (methacholine or exercise) when baseline spirometry is normal.
2. The Continuous Assess-Adjust-Review Loop
GINA organizes care around a continuous cycle:
- Assess: Audit symptom control, exacerbation risk, inhaler technique, adherence, comorbidities, and biomarkers. Standardized respiratory outcome tools are reviewed in our guide to SGRQ (St George’s Respiratory Questionnaire).
- Adjust: Step medication up or down, treat modifiable triggers, and issue a written asthma action plan.
- Review: Re-evaluate response at 1 to 3 months, auditing symptom scores, exacerbations, lung function, and side effects.
3. Elimination of SABA Monotherapy
Since 2019, GINA strongly advises against short-acting beta2-agonist (SABA) monotherapy across all severity steps. SABAs relieve acute bronchoconstriction without treating underlying mucosal inflammation. Regular SABA use downregulates beta2-receptors, increases airway hyperresponsiveness, and elevates severe exacerbation and mortality risks. Consequently, GINA mandates that all asthma patients receive an inhaled corticosteroid (ICS).
Types or related concepts
GINA stratifies adult and adolescent management into two distinct treatment tracks across five therapeutic steps, alongside dedicated severe asthma classifications.
| Framework / Track | Reliever Strategy | Controller Strategy | Primary Indication | Key Benefit & Risk Profile |
|---|---|---|---|---|
| Track 1 (Preferred): Anti-Inflammatory Reliever (AIR) | As-needed low-dose ICS-formoterol (Steps 1–5). | Steps 1–2: As-needed AIR only. Steps 3–5: Maintenance and Reliever Therapy (MART) with daily plus as-needed ICS-formoterol. | First-line pathway for adults and adolescents. | Reduces severe exacerbations by >30% vs SABA regimens; delivers steroid whenever symptoms occur. |
| Track 2 (Alternative): SABA Reliever Track | As-needed SABA (albuterol/salbutamol). | Step 1: Low-dose ICS taken with each SABA. Steps 2–5: Mandatory regular daily ICS or ICS-LABA controller. | Alternative when Track 1 is unavailable or contraindicated. | Higher exacerbation risk if daily controller is missed; risk of covert SABA overreliance. |
| Difficult-to-Treat Asthma | Track 1 or Track 2 reliever. | High-dose ICS-LABA or medium-dose MART, plus additional controllers. | Asthma uncontrolled despite medium- or high-dose controller prescription. | Driven largely by modifiable factors: poor adherence, incorrect technique (over 50% of patients), or comorbidities. |
| True Severe Asthma | Optimized AIR/MART or specialist reliever. | High-dose ICS-LABA plus add-on therapies (LAMA, biologics, macrolides). | Subset of difficult asthma (3–10%) uncontrolled despite confirmed adherence and technique. | Requires Type-2 biomarker phenotyping; candidate for targeted biologics (anti-IgE, anti-IL5/5R, anti-IL4Rα, anti-TSLP). |
| Asthma-COPD Overlap (ACO) | Rapid bronchodilator paired with mandatory ICS. | Combined ICS-LABA or triple therapy (ICS-LABA-LAMA). | Patients displaying clinical features of both asthma and COPD. | Mandates ICS inclusion; bronchodilator monotherapy without ICS is strictly contraindicated. |
Where it matters for labs, clinics or supply decisions
GINA guidelines shape operational protocols across clinical trials, diagnostic pulmonary laboratories, hospital formularies, and medical supply decisions.
1. Clinical Trial Protocol Standardization
In respiratory trials, GINA criteria benchmark recruitment and endpoint adjudication:
- Inclusion Verification: Protocols require documented bronchodilator reversibility (FEV1 >12% and >200 mL) within 12 months prior to screening to exclude non-asthmatic airway disease.
- Severity Categorization: GINA classifies asthma severity retrospectively by the treatment level required to maintain control, preventing misclassification from baseline symptom severity.
- Exacerbation Endpoints: Primary trial endpoints use GINA criteria for severe exacerbations (events requiring systemic corticosteroids for ≥3 days, emergency intervention, or hospital admission).
2. Diagnostic Biomarkers and Severe Asthma Phenotyping
GINA directs laboratory diagnostic panels before initiating targeted biologics:
- Blood Eosinophils: Complete blood count for absolute eosinophils (thresholds ≥150 or ≥300 cells/μL).
- Fractional Exhaled Nitric Oxide (FeNO): Testing (threshold ≥20–25 ppb) reflecting Type-2 airway inflammation.
- Serum IgE and Sensitization: Total and specific IgE testing alongside skin prick testing to confirm allergic status.
- Steroid Stewardship: Guides precision biologic selection to reduce toxic maintenance oral corticosteroids.
3. Clinical Supply and Inhaler Hardware Selection
Procurement officers align hardware purchasing with GINA standards:
- Spacer Delivery Systems: For pressurized metered-dose inhalers (pMDIs), GINA recommends valved holding chambers for children and adults with suboptimal technique. For assembly protocols, see our guide on how to use a spacer with an inhaler.
- Dose Counters: Procurement protocols mandate inhalers with integrated dose counters to prevent actuating empty canisters. Detailed canister construction is reviewed in our guide to parts of an inhaler.
- Emergency Respiratory Equipment: Facilities managing acute exacerbations must maintain validated nebulizers, high-flow oxygen delivery, and monitoring devices. Review system configurations in our overview of respiratory therapy equipment.
Common misunderstandings
Several clinical and operational misconceptions surround GINA guidance:
- Misunderstanding: SABA inhalers alone are safe for “mild” asthma.
Reality: Patients with infrequent symptoms still suffer fatal exacerbations; 15% to 20% of asthma deaths occur in mild disease. Every patient requires an ICS-containing regimen. - Misunderstanding: GINA is a national regulatory mandate.
Reality: GINA is an independent global strategy collaborative, not a government regulator. Recommendations are adapted by national bodies based on local formulary approvals. - Misunderstanding: Track 1 (ICS-formoterol) can utilize any LABA.
Reality: Formoterol is uniquely suited for Track 1 because it combines rapid bronchodilator onset (1 to 3 minutes) with a 12-hour duration. Slower LABAs (like salmeterol) cannot be used as relievers. - Misunderstanding: Asthma severity can be judged at initial presentation.
Reality: Severity cannot be determined before treatment starts. GINA assesses severity retrospectively after several months of controller therapy, distinguishing poor adherence from true severe asthma.
Frequently asked questions
What does GINA stand for in medical guidelines?
GINA stands for the Global Initiative for Asthma. It is an international collaborative founded in 1993 by the World Health Organization (WHO) and the National Heart, Lung, and Blood Institute (NHLBI) to reduce asthma burden globally through evidence-based clinical strategies.
Why did GINA stop recommending SABA-only treatment?
GINA discontinued short-acting beta2-agonist (SABA) monotherapy because SABAs relieve bronchospasm without addressing underlying airway inflammation. Regular SABA use downregulates beta-receptors, increases airway hyperresponsiveness, leads to dangerous overreliance, and substantially increases severe exacerbation and mortality risks.
What is GINA Track 1 therapy?
GINA Track 1 is the preferred treatment pathway for adults and adolescents. It uses low-dose inhaled corticosteroid (ICS) combined with formoterol as the reliever across all steps. In mild asthma, it is taken as-needed only; in moderate-to-severe asthma, it serves as Maintenance and Reliever Therapy (MART).
What is the GINA Assess-Adjust-Review cycle?
The Assess-Adjust-Review cycle is GINA’s continuous management framework. Clinicians assess symptom control, exacerbation risk, inhaler technique, and comorbidities; adjust pharmacotherapy and asthma action plans; and review clinical response and lung function every 1 to 3 months.
Sources
- GINA Science Committee / Reddel HK et al. (read 2026-11-09). “2026 Global Initiative for Asthma (GINA) Strategy Report: Executive Summary and Key Changes.” Am J Respir Crit Care Med / Eur Respir J. PMID: 42847657. NCBI PubMed
- JAMA Network Open (read 2026-11-09). “Global Initiative for Asthma Updates for Diagnosing Asthma in Adults.” JAMA Netw Open 2026. PMID: 42172033. NCBI PubMed
- World Health Organization (read 2026-11-09). “Asthma Key Facts and Global Burden.” WHO Fact Sheets. WHO Official Site
- GOLD & GINA Joint Scientific Perspective (read 2026-11-09). “Addressing the Global Challenges of COPD and Asthma: A Shared Vision.” Arch Bronconeumol. PMID: 41628954. NCBI PubMed
